A Non-Interventional Survey Study on the Preferences of Patients with AtrialFibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
M
Michael Moran, MD
Primary Investigator
Enrolling By Invitation
18 years - 100 years
All
Phase
N/A
1 participants needed
1 Location
Brief description of study
What is the purpose of this study?
To identify the relative importance of attributes of anticoagulant treatment to AF patients and physicians that treat AF patients To quantify the tradeoffs that patients and physicians are willing to make between attributes associated with anticoagulant treatment.
THIS STUDY IS ENROLLING BY INVITATION ONLY - This study is only enrolling individuals who have already participated in the Phase 3 LIBREXIA AF study.
Detailed description of study
What will happen during the study?
- Participants will be asked to complete a survey during an in-person study visit on the same electronic tablet that is also used for the LIBREXIA AF study.
- The survey will take about 30 minutes to complete.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Atrial fibrillation., AF
-
Age: 18 years - 100 years
-
Gender: All
Inclusion criteria:
- Patients with AF enrolled at US sites in the LIBREXIA AF Phase 3 study
Updated on
16 Dec 2024.
Study ID: BALL-JANSSEN-PREFERENCE, 25037
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
